In breast cancer, this is often achieved by genetic/epigenetic ablation (mutations/deletions/promoter-silencing) of RB, or by hyper-phosphorylation of the protein, pRB, through activation of cyclin dependent kinases CDK4/6 and CDK233. This evidence concerns the gene RB1 and breast carcinoma.